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Poster Session I S249(p 5 0.01). Likewise, the probability or relapse was highest in the
MK1 group (72%) as compared to the MK- group (37%), the CN
group (24%), or the CBF group (14%) (p 5 0.001). There was no
statistically significant difference in non-relapse mortality between
the four groups.
Conclusions:Our results indicate that cytogenetics is still one of the
most important prognostic factors. In particular, the presence of
a monosomal karyotype provides a strong negative prognostic pre-
diction for patients with AML undergoing alloSCT. These patients
should be referred to alloSCT in early in CR1.260
SYNERGISTIC CYTOTOXICITY OF BUSULFAN AND NUCLEOSIDE ANALOGS
IN HUMAN LYMPHOID CELL LINES
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Lymphoid leukemia and Non-Hodgkin’s lymphoma (NHL) are
heterogeneous diseases, which require various treatment modalities.
Although the success of hematopoietic stem cell transplantation
(HSCT) for myeloid leukemia has been well documented in the
last decade, advances in lymphoid malignancies have been modest
and the efficacy of HSCT for these diseases merits further study.
To identify potential efficacious pretransplant conditioning therapy
for these diseases, we performed in vitro cellular studies on the pos-
sible synergistic cytotoxicity of the DNA-alkylating agent busulfan
(Bu) and nucleoside analogs (NA) clofarabine (Clo), fludarabine
(Flu) and gemcitabine (Gem). Daudi (B cell lymphoblast), J45.01
(T cell lymphoblast) and U937 (monocytic/lymphoblast) cells were
exposed to these drugs, either individually or in combinations, and
analyzed for cell survival by the MTT assay and for protein level
and modifications by Western blot analysis. The three cell lines ex-
hibited different drug sensitivities as suggested by the IC50 values:
Daudi – 40 mM Bu, 80 nM Clo, 30 mM Flu and 2 nM Gem; J45.01
– 100 mM Bu, 60 nM Clo, 0.8 mM Flu and 25 nM Gem; U937 -
160 mM Bu, 20 nM Clo, 1.2 mM Flu and 70 nM Gem. Synergistic
cytotoxicities were observed when the drugs were combined at
IC10 – IC20 concentrations with U937 cells being the most sensitive.
Exposure of cells to [Gem1Clo1Bu], [Gem1Flu1Bu] or [Clo1-
Flu1Bu] for 4 days resulted in 5%-15% survival of U937 cells,
20%-50% of Daudi cells and 45%-80% of J45.01 cells. The effects
of these drug combinations on cell survival are consistent withDNA-
damage response as indicated by the phosphorylation of H2AX,
ATM and SMC1 proteins, and cleavage of PARP-1. The observed
methylations of histone 3 may suggest chromatin remodeling which
may contribute to the pronounced activity of [NA1Bu] combina-
tions. Interestingly, [twoNA1 Bu] combinations are muchmore ef-
ficacious than [one NA1 Bu]. Exposure of Daudi, J45.01 and U937
cells to [Gem1Bu] for 4 days resulted in 85%, 100% and 78% cell
survival, respectively. Similar exposure to [Gem1Clo1Bu] resulted
in 50%, 60% and 5% survival and exposure to [Gem1Flu1Bu] re-
sulted in 20%, 80% and 6% survival of Daudi, J45.01, and U937
cells, respectively. Our results suggest that combination of two NA
with Bu may be more active than Bu plus one NA. The findings sup-
port the introduction of [twoNA1 Bu] as part of pretransplant con-
ditioning regimen for advanced, aggressive lymphoid malignancies.261
ALLOGENEIC AND AUTOLOGOUS TRANSPLANTATION FOR THE TREAT-
MENT OF ADULT ALL
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Introduction: The Philadelphia chromosome translocation ([Ph1)
is the most frequent cytogenetic abnormality detected in adult ALL.
Ph1 patients are classified as high-risk, with allogeneic hematopoi-
etic stem cell transplantation (alloHCT) considered the best chance
for cure. The role of autologous transplantation (autoHCT) in the
treatment of these patients remains controversial. More recently, ty-rosine kinase inhibitors (TKIs) have shown promise in treating Ph1
ALL. The long-term outcomes with TKI’s plus chemotherapy re-
main poor, consequently transplantation is still considered standard.
AtUCSF, Ph1ALLpatients without histocompatible donors are of-
fered autoHCT. In this study we retrospectively analyzed adult ALL
patients undergoing alloHCT and autoHCT at UCSF from 1986 to
2009 to identify factors influencing outcome.
Patients and Methods: 121 patients diagnosed with ALL under-
went autoHCT or alloHCT at UCSF since 1986. 42 patients were
Ph positive; based on cytogenetic and/or molecular methods. The
mean age at transplant was 36 overall (15-64), and 43 for Ph1 pa-
tients (23-64). Patients received autoHCT or alloHCT based on do-
nor availability. Overall, 43 patients underwent autoHCT, and 78
underwent alloHCT. For the Ph1 subgroup, 13 and 29 received au-
toHCT and alloHCT respectively. Conditioning consisted of either
total body irradiation (TBI) with etoposide and/or cyclophospha-
mide; or fludarabine with busulfan. AlloHCT patients received stan-
dard GVHD prophylaxis, and all patients received ID prophylaxis.
Results: The median disease-free survival (DFS) overall was 1.59
years for patients receiving autoHCT and 1.7 years for those receiv-
ing alloHCT. The 5-year probability of DFS was 38% for au-
toHCT, and 44% for alloHCT with treatment-related mortality
of 9% and 36%, respectively. In the subset of Ph1 patients, 5-year
probability of DFS was 58% and 40%, respectively, with no signifi-
cant difference detected. Improved DFS with noted following TKI
use (70% in the autologous group, n10; 58% in the allogeneic group,
n17). Status at transplantation correlated with probability of DFS.
TBI-based regimens and age were not found to influence outcomes.
Conclusion:Our data support the use of alloHCT for the treatment
of ALL, including Ph1 patients. The data with autoHCT are en-
couraging, with impressive results found following the addition of
TKI therapy. A larger Phase II study evaluating the role of autoHCT
in PH1 ALL appears warranted.262
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The purine nucleoside analogs fludarabine (Flu) and clofarabine
(Clo) were recently shown to have synergistic cytotoxic activity
when combined with busulfan (Bu) in AML cell lines and in primary
explanted AML cells. We attributed most of this synergism to ATM
pathway activation and chromatin remodeling. We have now ex-
tended these studies to include gemcitabine (Gem), a pyrimidine nu-
cleoside analog, and determined their efficacy and synergism in
myeloid cells including two AML cell lines (KBM3/Bu2506 and
OCI-AML3) and two CML cell lines (B5/Bu2506 and KBM5).
Combination of sub-lethal (IC10 – IC20) concentrations of the re-
spective agents [Flu1Clo1Bu] was demonstrated to be synergisti-
cally cytotoxic to both AML cell lines and KBM5 but less active
against B5/Bu2506 cells. Similar results were obtained when cells
were exposed to sub-lethal concentations (IC10 – IC20) of
[Clo1Gem1Bu] and [Flu1Gem1Bu] suggesting that replacement
of either Clo or Flu with Gem in triple-drug exposure did not result
in significantly different phenotypic responses.Western blot analysis
indicates DNA-damage response as shown by the activation of ATM
and apoptotic pathways in cells exposed to triple-drug combinations.
Since chromatin remodeling is involved in the efficacy of [Clo1
Flu1Bu] in AML cells, we hypothesize that similar mechanism is in-
volved in the efficacy of [Clo1Gem1Bu] and [Flu1Gem1Bu]. Al-
though limited in sample size, our present and published studies
suggest that combination of Bu with two nucleoside analogs as
part of pretransplant therapy will be more efficacious against
AML. However, the relative resistance of B5/Bu2506 cells and sensi-
tivity of KBM5 cells to triple-drug combinations suggests varied re-
sponses of CML cells. Further experiments using additional CML
cell lines and primary explanted CML cells are warranted to define
the relevance of [nucleoside analogs1Bu] combinations in pretrans-
plant regimen for CML patients who will undergo hematopoietic
S250 Poster Session Istem cell transplantation. Overall, we propose that combination of
Bu with 2 nucleoside analogs ban be utilized to improve currently
available treatment programs for advanced myeloid leukemias.263
LONG-TERM SURVIVAL AFTER T-CELL DEPLETED ALLOGENEIC STEM
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T-cell depleted allogeneic hematopoietic stem cell transplants
(TCD-HSCT) have demonstrated durable disease free survival
with a low risk of graft vs. host disease (GVHD) in patients with
AML, MDS and NHL.We investigated this approach in 60 consec-
utive adult patients with ALL who underwent TCD-HSCT from
May 1997 through December 2008. Patients received myeloablative
cytoreduction consisting of hyperfractionated total body irradiation
(1375-1500cGy), followed by thiotepa (10mg/kg) and either cyclo-
phosphamide (120mg/kg, n 5 22) or fludarabine (125mg/m2, n 5
38). No immunosuppressive agents were used post-HSCT. There
were 39 males and 21 females. The median age was 36 years (range,
18-63). Twenty-seven patients were in hematologic CR1, 18 in CR2,
11 in CR3 or greater, and 4 patients had relapsed or refractory dis-
ease. Baseline cytogenetics were classified as poor risk (n 5 26, in-
cluding Ph1 5 17), standard risk (n 5 26), good risk (n 5 4) or
non-evaluable (n 5 4). Forty-eight patients had a B-cell and 10
a T cell phenotype (multilineage 5 1, unknown 5 1). Bone marrow
grafts were depleted of T-cells by soybean lectin agglutination and
sheep erythrocyte rosette depletion and PBSC grafts underwent
CD341 positive selection using the ISOLEX 300i Magnetic Cell
Separator and sheep erythrocyte rosette depletion. Twenty-four pa-
tients received grafts from HLA matched related donors (MRD), 8
from a single allele disparate related donor (MMRD), 15 from
HLAmatched unrelated donors (MUD), 13 fromHLAmismatched
unrelated donors (MMUD).With a median follow-up of 8.4 months
(range 0.2-149 months), 5-year overall survival (OS) and progres-
sion-free-survival (PFS) were 45% and 30%, respectively. The re-
lapse rate was 30% in patients in CR at time of HSCT. The 4
patients with relapsed or refractory disease died of relapse (n 5 3)
or infection (n 5 1). Ten of 58 evaluable patients (17%) developed
grade 2-3 aGVHD post-HSCT (MRD 5 2, MUD 5 3, MMRD
5 4, MMUD 5 1); cGVHD occurred in 13% evaluable patients.
We examined factors that predict outcomes in patients with ALL,
and we found that only disease status at time of HSCT predicted
PFS (p \ 0.001). Pre-HSCT LDH was predictive of OS (p 5
0.047). No effect was observed for cytogenetics, WBC at diagnosis,
or presence of extramedullary disease. While TCD-HSCT does
provide acceptable OS and PFS without GVHD in adult patients
with ALL, relapse remains a limiting factor. Future studies focusing
on novel conditioning regimens and/or maintenance therapy are
warranted.264
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Introduction: Leukemic relapse following initial induction chemo-
therapy has been predicted independently by the rate of peripheral
blast clearance in adult AML and pediatric ALL. This early response
to therapy in de-novo acute leukemia may indicate in-vivo chemo-
sensitivity of malignant cells. No reports exist on whether blastresponse is predictive of relapse after myeloablative conditioning
for allogeneic hematopoietic stem cell transplantation (AlloHSCT).
Methods:We analyzed 69 patients with AML (n 5 47), MDS (n 5
17), and ALL (n5 5) who had circulating blasts prior to busulfan- or
TBI-based myeloablative AlloHSCT at a single academic center
from 1998 to 2009. Individual regression slopes for consecutive
values of circulating blasts were calculated throughout conditioning
chemotherapy. Relapse-free (RFS) and overall survival (OS) were es-
timated by Kaplan-Meier method and Cox proportional hazards
model.
Results: The median age of patients (49% males) was 47 years
(range, 20-62). 31 (45%) receivedmore than one prior chemotherapy
regimen; 31 (45%) had unrelated donor AlloHSCT; 14 (20%) re-
ceived TBI-based preparation; 34 (49%) relapsed after AlloHSCT.
50 (73%) patients were able to clear their circulating blasts within
median of 6.5 days (range, 2-10). Time to blast clearance was associ-
atedwith underlyingmalignancy (median of 4, 7, and 8 days for ALL,
MDS, and AML respectively, p\ 0.001) and myeloablative condi-
tioning (median of 4 days for TBI- vs. 8 days for busulfan-based
preparation, p \ 0.001). Median average slope of blast clearance
was -15.9 per day (range, -65.2 to 10.3). Neither velocity of blast de-
cline (p5 0.4) nor the number of days to circulating blast clearance (p
5 0.35) was predictive for time to disease relapse.More than one pre-
vious chemotherapy was associated with higher relapse rate (hazard
ratio [HR]5 2.5, p\0.01) andworseOS (HR5 2.2, p\0.01), while
receiving TBI-containing preparation portended poor OS (HR 5
2.3, p\ 0.01) in multivariable analysis.
Conclusions: The number of previous chemotherapies, but not the
slope of circulating blast decline during myeloablative conditioning
for AlloHSCT, predicted disease relapse and OS in patients with cir-
culating blasts.265
MOST PATIENTS WITH CBF LEUKEMIA WILL REQUIRE HSCT FOR LONG
TERM DISEASE CONTROL: RESULTS OF COHORT OF UNSELECTED
PATIENTS
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Patients with CBF-AML are regarded as having a favorable out-
come when treated with anthracycline-based induction chemother-
apy and multiple cycles of high-dose cytarabine consolidation.
Most data indicating the favorable prognosis of CBF-AML with
non-HSCT management originates from young selected patients
participating in clinical trials with scarce information on salvage
treatment. We performed a retrospective analysis of 30 consecutive
patients diagnosed with CBF-AML (14 with t(8;21) and 16 with inv
(16)) at a regional leukemia center over twelve years to assess long
term survival and the likelihood of therapeutic success without
ever requiring HSCT. We reviewed the charts of all patients with
CBF-AML (irrespective of other cytogenetic abnormalities) to ex-
tract demographic, treatment, and outcome information. Survival
status and subsequent treatments in other institutions were deter-
mined by contacting the patient, attending physician or review of
public death records. All patients were treated with curative intent
with anthracycline-based induction therapy, and 47% were on clin-
ical trials. Median age at diagnosis was 43 years (range 18-69). There
was 1 death during induction therapy and 22/29 patients (73.3%)
achieved a complete remission with initial induction therapy. Me-
dian follow up for survivors was 35.3 months (range 6.4-117.4)
with all survivors currently in remission. Overall 13 patients
(43.3%) have required some modality of HSCT. Six patients re-
ceived HSCT in CR1 due to perceived high risk of relapse (5 autol-
ogous, 1 allogeneic), none of which have relapsed. Among the 16
patients receiving non-transplant consolidation in CR1, 6 have sub-
sequently relapsed and required aHSCT (3 autologous, 3 allogeneic)
and 3 of these patients are alive 20.9-117.4 months from the initial
diagnosis. Seven patients received HSCT in CR2 or in relapse (4 au-
tologous, 3 allogeneic) and 6 of these patients are long-term survi-
vors. Estimated 5 year overall survival for the entire cohort is 58.8
1/- 10.8%, comparable to what has been described for younger pa-
tients entering clinical trials (Grimwade et al, 2010). The likelihood
